ProLynx extends lead in half-life extension platform technology – Shows primary deuterium kinetic isotope effects prolong drug release and polymer biodegradation in a drug delivery system
April 03, 2018 09:00 ET
|
ProLynx LLC
SAN FRANCISCO, April 03, 2018 (GLOBE NEWSWIRE) -- ProLynx announced today the publication of a paper demonstrating its leading capabilities to exploit primary deuterium kinetic isotope effects...
プロリンクス、デュアル受容体アゴニストの新技術開発に向け、SBIR助成金を獲得
September 26, 2017 04:16 ET
|
ProLynx LLC
サンフランシスコ発, Sept. 26, 2017 (GLOBE NEWSWIRE) -- プロリンクス (ProLynx) は本日、単一の媒体で2つ以上の薬剤のデリバリーをコントロールする技術プラットフォームを拡張するために、NIHから中小企業技術革新制度 (Small Business Innovation Research、SBIR)...
ProLynx announces SBIR grant award to develop novel technology for dual receptor agonists
September 25, 2017 09:00 ET
|
ProLynx LLC
SAN FRANCISCO, Sept. 25, 2017 (GLOBE NEWSWIRE) -- Today, ProLynx announced it was awarded a Small Business Innovation Research (SBIR) grant from the NIH to expand its technology platform to control...
プロリンクス、眼中薬物送達システムの評価における第一三共との協力を発表
June 19, 2017 09:00 ET
|
ProLynx LLC
サンフランシスコ発, June 19, 2017 (GLOBE NEWSWIRE) -- プロリンクス (ProLynx LLC) は本日、同社の眼中での薬物送達リンカー技術を評価するために、第一三共株式会社 (Daiichi Sankyo Company, Limited) と協力することを発表した。 ...
ProLynx announces collaboration with Daiichi Sankyo to evaluate drug delivery system in the eye
June 19, 2017 09:00 ET
|
ProLynx LLC
SAN FRANCISCO, June 19, 2017 (GLOBE NEWSWIRE) -- Today ProLynx LLC announced a collaboration with Daiichi Sankyo Company, Limited to evaluate its drug delivery linker technology in the eye. In...
プロリンクス、glp-1受容体アゴニストの月1回投与をサポートするハイドロゲル･ミクロスフェア薬物送達システム、「plx039」を発表
June 12, 2017 14:55 ET
|
ProLynx LLC
サンフランシスコ, June 13, 2017 (GLOBE NEWSWIRE) -- サンディエゴで開催中の米国糖尿病学会第77回会議の最新の要旨において、プロリンクス (ProLynx LLC) は、2型糖尿病 (T2D) の治療のためのGLP-1受容体アゴニスト (GLP-1RA) の月1回の皮下 (SC)...
ProLynx announces PLX039, a hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist
June 12, 2017 09:00 ET
|
ProLynx LLC
SAN FRANCISCO, June 12, 2017 (GLOBE NEWSWIRE) -- In a late-breaking abstract at the 77th American Diabetes Association meeting in San Diego, ProLynx LLC announced a novel drug delivery system to...
ProLynx issued US patent for cleavable linker technology on hydrogels
May 30, 2017 20:03 ET
|
ProLynx LLC
SAN FRANCISCO, May 30, 2017 (GLOBE NEWSWIRE) -- ProLynx LLC today announced that the United States Patent and Trademark Office has issued US Patent 9,649,385 entitled “Hydrogels with Biodegradable...
ProLynx Awarded NSF Supplement to Develop Its Hydrogel Drug Delivery System to Treat Inner Ear Disorders
June 29, 2015 17:21 ET
|
ProLynx Inc.
SAN FRANCISCO, June 29, 2015 (GLOBE NEWSWIRE) -- ProLynx LLC, a biotechnology company focused on development of disruptive drug delivery systems for half-life extension, announced the receipt of a...
ProLynx Announces Active IND of a Novel Ultra-Long Acting PEG–SN-38 Conjugate to Treat Solid Tumors
June 02, 2015 14:05 ET
|
ProLynx Inc.
SAN FRANCISCO, June 02, 2015 (GLOBE NEWSWIRE) -- ProLynx LLC announced today that an Investigational New Drug (IND) application for their novel, ultra-long acting PEG~SN-38 (PLX-0264; DFP-13318)...